Moleculin Biotech (NASDAQ:MBRX) Upgraded to “Buy” at Maxim Group
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) was upgraded by analysts at Maxim Group from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a $4.00 price objective on the stock. Maxim Group’s target price would indicate a potential upside of 273.83% from […]
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) was upgraded by analysts at Maxim Group from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a $4.00 price objective on the stock. Maxim Group’s target price would indicate a potential upside of 273.83% from […]
